289 related articles for article (PubMed ID: 31781842)
1. The promise and peril of targeting cell metabolism for cancer therapy.
Weiss JM
Cancer Immunol Immunother; 2020 Feb; 69(2):255-261. PubMed ID: 31781842
[TBL] [Abstract][Full Text] [Related]
2. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
3. Harnessing tumor-associated macrophages as aids for cancer immunotherapy.
Li X; Liu R; Su X; Pan Y; Han X; Shao C; Shi Y
Mol Cancer; 2019 Dec; 18(1):177. PubMed ID: 31805946
[TBL] [Abstract][Full Text] [Related]
4. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.
El Hassouni B; Granchi C; Vallés-Martí A; Supadmanaba IGP; Bononi G; Tuccinardi T; Funel N; Jimenez CR; Peters GJ; Giovannetti E; Minutolo F
Semin Cancer Biol; 2020 Feb; 60():238-248. PubMed ID: 31445217
[TBL] [Abstract][Full Text] [Related]
5. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
6. Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance.
Traba J; Sack MN; Waldmann TA; Anton OM
Front Immunol; 2021; 12():657293. PubMed ID: 34079545
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.
Poff A; Koutnik AP; Egan KM; Sahebjam S; D'Agostino D; Kumar NB
Semin Cancer Biol; 2019 Jun; 56():135-148. PubMed ID: 29294371
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of targeting cancer metabolism for cancer therapy.
Farhadi P; Yarani R; Dokaneheifard S; Mansouri K
Tumour Biol; 2020 Oct; 42(10):1010428320965284. PubMed ID: 33028168
[TBL] [Abstract][Full Text] [Related]
9. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
10. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
Front Immunol; 2020; 11():573326. PubMed ID: 33178201
[TBL] [Abstract][Full Text] [Related]
11. Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target.
Ocaña MC; Martínez-Poveda B; Quesada AR; Medina MÁ
Med Res Rev; 2019 Jan; 39(1):70-113. PubMed ID: 29785785
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor associated macrophages (TAMs) via nanocarriers.
Singh Y; Pawar VK; Meher JG; Raval K; Kumar A; Shrivastava R; Bhadauria S; Chourasia MK
J Control Release; 2017 May; 254():92-106. PubMed ID: 28377038
[TBL] [Abstract][Full Text] [Related]
14. Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship.
Netea-Maier RT; Smit JWA; Netea MG
Cancer Lett; 2018 Jan; 413():102-109. PubMed ID: 29111350
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
Allison KE; Coomber BL; Bridle BW
Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
[TBL] [Abstract][Full Text] [Related]
16. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
17. Lactate in the tumour microenvironment: From immune modulation to therapy.
Wang ZH; Peng WB; Zhang P; Yang XP; Zhou Q
EBioMedicine; 2021 Nov; 73():103627. PubMed ID: 34656878
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
19. Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways.
Fumarola C; Petronini PG; Alfieri R
Biochem Pharmacol; 2018 May; 151():114-125. PubMed ID: 29530507
[TBL] [Abstract][Full Text] [Related]
20. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
Front Immunol; 2019; 10():1399. PubMed ID: 31275326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
